COVID-19 vs Influenza vs RSV
Direct answer: COVID-19, influenza and RSV cause overlapping respiratory symptoms, so a combined multiplex antigen test detects all three in one device — faster and cheaper than running three separate tests.
Comparison table
| COVID-19 | Influenza | RSV | |
|---|---|---|---|
| Pathogen | SARS-CoV-2 | Influenza A/B | Respiratory syncytial virus |
| Peak risk | All ages | All ages | Infants / elderly |
| Seasonality | Year-round | Winter | Winter |
| Rapid test target | Nucleocapsid antigen | Nucleoprotein antigen | Fusion protein antigen |
What each test detects
- COVID-19: SARS-CoV-2 nucleocapsid antigen.
- Influenza: influenza A and B nucleoprotein antigens.
- RSV: RSV fusion protein antigen.
Testing context
During respiratory season the three viruses circulate together and present similarly; multiplex testing supports faster isolation and treatment decisions.
Strengths
- Multiplex combo: one sample, one device, three results — saves time and cost.
- Single targets: simpler readout and lower cost when one pathogen is suspected.
Limitations
- Antigen tests: lower sensitivity than PCR; negative results during high prevalence may need confirmation.
False negative / positive considerations
- False negative: low viral load, early or late sampling.
- False positive: rare; confirm clinically or by PCR if discordant.
Confirmatory testing
PCR remains the reference for respiratory viruses; rapid antigen tests are for point-of-care screening.
Procurement considerations
Stock combined COVID/Flu/RSV combos for winter syndromic demand; they are the higher-utility, higher-margin SKU.
Related pages
Which test to choose
Choose a multiplex combo during respiratory season — one sample, one device, three results, supporting faster isolation and treatment decisions.
| Scenario | Recommended |
|---|---|
| Winter syndromic season | Multiplex combo |
| Single pathogen suspected | Single-target test |
Sources: WHO COVID-19 guidance; CDC influenza and RSV guidance.
Last reviewed: 2026-09-12